GenSight Biologics trades up after €46m Paris IPO
GenSight Biologics, a niche French biotechnology firm focused on treating degenerative retinal and nervous system disorders, has completed its all-primary IPO on Euronext Paris, raising €46m to help bring its flagship drug GS010 to market in Europe and the US.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: